Home / Companies / Bicara Therapeutics Inc. / 9 Jun 2026
Bicara Therapeutics Inc.: meeting of 9 Jun 2026
Votes reported on Form N-PX, item by item
89 Form N-PX filers reported votes at the Bicara Therapeutics Inc. meeting of 9 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 69.3% of reported votes for; 32 filers withheld from or voted against at least one nominee.
327 vote records from 88 filers. 21 of the 87 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
1 vote records from 1 filers. No filer marked a management recommendation, so no against-management figure is reported. 1 filer reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
164 vote records from 88 filers. 0 of the 87 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 3. Auditor |
|---|---|---|
| Vanguard | For | For |
| BlackRock and iShares | For | For |
| Fidelity | For | For |
| Dimensional | Abstain or withhold * | For |
| State Street and SPDR | For | For |
| American Century | Abstain or withhold * | For |
| Franklin Templeton | For | For |
| Invesco | For | For |
| Equitable | For | For |
| Charles Schwab | For | For |
| Nuveen and TIAA | For | For |
| ProShares and ProFunds | Abstain or withhold * | For |
| John Hancock and Manulife | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For |
| J.P. Morgan | For | For |
| Goldman Sachs | For | For |
| PGIM and Prudential | For | For |
| Jackson National funds | Abstain or withhold * | For |
| Northern Trust and FlexShares | For | For |
| SEI | For | For |
| T. Rowe Price | For | For |
| Lincoln Financial | Abstain or withhold | For |
| Voya | For | For |
| Nationwide | For | For |
| Victory Capital | Abstain or withhold * | For |
| Brighthouse Funds | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For |
| Columbia Threadneedle | For | For |
| Principal | Abstain or withhold * | For |
| Pacific Life funds | For | For |
| Global X | For | For |
| Transamerica | For | For |
| DWS | Abstain or withhold * | For |
| Virtus | Abstain or withhold * | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Bicara Therapeutics Inc. meeting?
89 Form N-PX filers reported votes at the meeting of 9 Jun 2026. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Bicara Therapeutics Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Bicara Therapeutics Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Bicara Therapeutics Inc. with a meeting date within three days of 9 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.